When Genae Girard received a diagnosis of breast cancer in 2006, she did not expect to run into patent problems.
Girard took a genetic test to see if her genes also put her at increased risk for ovarian cancer, which might require the removal of her ovaries. The test came back positive, so she wanted a second opinion from another test. But there can be no second opinion. A decision by the government more than 10 years ago allowed one company, Myriad Genetics, to own the patent on two genes that are associated with increased risk for breast cancer and ovarian cancer, and on the testing that measures that risk.
On Tuesday, Girard, 39, who lives in the Austin, Texas, area, filed a lawsuit against Myriad and the US Patent Office, challenging the decision to grant a patent on a gene to Myriad and companies like it. She was joined by four other cancer patients, by professional organizations of pathologists with more than 100,000 members and by several individual pathologists and genetic researchers.
PHOTO: NY TIMES NEWS SERVICE
The lawsuit was organized by the American Civil Liberties Union (ACLU) and filed in federal court in New York. It blends patent law, medical science, breast cancer activism and an unusual civil liberties argument in ways that could make it a landmark case.
Companies like Myriad, based in Salt Lake City, Utah, have argued that the patent system promotes innovation by giving companies the temporary monopoly that rewards their substantial investment in research and development.
The plaintiffs do not accuse Myriad of being a poor steward of the information concerning the two genes at issue in the suit, known as BRCA1 and BRCA2, but they argue that BRCA testing would improve if market forces were allowed to work.
Harry Ostrer, director of the human genetics program at the New York University School of Medicine and a plaintiff in the case, said many laboratories could perform the BRCA tests faster than Myriad and for less money.
Laboratories like his, he said, could focus on the mysteries still unsolved in gene variants. But if he tried to offer such services today, he said, he would be risking a lawsuit from Myriad.
Christopher Hansen, senior national staff counsel for the ACLU, said the problem was with the patent office, not the company.
He recalled that when he first heard that the office had granted a patent for a gene, “I said that can’t be true.”
Patents are normally not granted for products of nature or laws of nature. The companies successfully argued that they had done something that made the genes more than nature’s work: They had isolated and purified the DNA, and thus had patented something they had created — even though it corresponded to the sequence of an actual gene.
Thousands gathered across New Zealand yesterday to celebrate the signing of the country’s founding document and some called for an end to government policies that critics say erode the rights promised to the indigenous Maori population. As the sun rose on the dawn service at Waitangi where the Treaty of Waitangi was first signed between the British Crown and Maori chiefs in 1840, some community leaders called on the government to honor promises made 185 years ago. The call was repeated at peaceful rallies that drew several hundred people later in the day. “This government is attacking tangata whenua [indigenous people] on all
RIGHTS FEARS: A protester said Beijing would use the embassy to catch and send Hong Kongers to China, while a lawmaker said Chinese agents had threatened Britons Hundreds of demonstrators on Saturday protested at a site earmarked for Beijing’s controversial new embassy in London over human rights and security concerns. The new embassy — if approved by the British government — would be the “biggest Chinese embassy in Europe,” one lawmaker said earlier. Protester Iona Boswell, a 40-year-old social worker, said there was “no need for a mega embassy here” and that she believed it would be used to facilitate the “harassment of dissidents.” China has for several years been trying to relocate its embassy, currently in the British capital’s upmarket Marylebone district, to the sprawling historic site in the
A deluge of disinformation about a virus called hMPV is stoking anti-China sentiment across Asia and spurring unfounded concerns of renewed lockdowns, despite experts dismissing comparisons with the COVID-19 pandemic five years ago. Agence France-Presse’s fact-checkers have debunked a slew of social media posts about the usually non-fatal respiratory disease human metapneumovirus after cases rose in China. Many of these posts claimed that people were dying and that a national emergency had been declared. Garnering tens of thousands of views, some posts recycled old footage from China’s draconian lockdowns during the COVID-19 pandemic, which originated in the country in late
BACK TO BATTLE: North Korean soldiers have returned to the front lines in Russia’s Kursk region after earlier reports that Moscow had withdrawn them following heavy losses Ukrainian President Volodymyr Zelenskiy on Friday pored over a once-classified map of vast deposits of rare earths and other critical minerals as part of a push to appeal to US President Donald Trump’s penchant for a deal. The US president, whose administration is pressing for a rapid end to Ukraine’s war with Russia, on Monday said he wanted Ukraine to supply the US with rare earths and other minerals in return for financially supporting its war effort. “If we are talking about a deal, then let’s do a deal, we are only for it,” Zelenskiy said, emphasizing Ukraine’s need for security guarantees